Cancer Biological Therapy Market Size, Share, Growth Analysis, By Product(Cancer Growth Blockers, Monoclonal Antibodies), By Distribution Channel(Hospital And Retail & Mail Order Pharmacies) - Industry Forecast 2024-2031

Cancer Biological Therapy Market size was valued at USD 77 billion in 2021 and is poised to grow from USD 79.50 billion in 2022 to USD 136.6 billion by 2030, at a CAGR of 7 % during the forecast period (2023-2030).

The competitive landscape of the cancer biological therapy market offers comprehensive details about each competitor. These details include company overview, company financials, revenue generated, market potential, research and development investments, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches, product range, application dominance, and other relevant data points specifically related to the companies' involvement in the cancer biological therapy market. 'F. Hoffmann-La Roche Ltd - Switzerland', 'Bristol-Myers Squibb Company - United States', 'Novartis AG - Switzerland', 'Amgen Inc. - United States', 'Merck & Co., Inc. - United States', 'Pfizer Inc. - United States', 'AstraZeneca - United Kingdom', 'Eli Lilly and Company - United States', 'GlaxoSmithKline plc - United Kingdom', 'Sanofi - France', 'Takeda Pharmaceutical Company Limited - Japan', 'Johnson & Johnson Services, Inc. - United States', 'AbbVie Inc. - United States', 'Gilead Sciences, Inc. - United States', 'Bayer AG - Germany', 'Celgene Corporation (acquired by Bristol-Myers Squibb) - United States', 'Astellas Pharma Inc. - Japan', 'Biogen Inc. - United States', 'Daiichi Sankyo Company, Limited - Japan', 'Seattle Genetics, Inc. - United States'

The increasing number of cancer cases worldwide is a significant driver fueling the growth of the cancer biological therapy market during the forecast period. According to reports from the American Cancer Society, there has been a notable rise in Small Cell Lung Cancer (SCLC) cases, with a majority occurring in individuals between the ages of 60 and 80 years. The estimated death rate from SCLC is approximately 30,000 per year. Additionally, data from the World Health Organization (WHO) reveals that lung cancer ranks as the second most prevalent cancer in both men and women, causing 1.59 million deaths in 2012. These alarming statistics contribute to the surge in demand for cancer biological therapies, propelling market growth to address the increasing burden of cancer on a scale.

The growing emphasis on personalized and targeted medicines is one major market trend in the market for cancer biological therapies. The distinctive genetic and molecular properties of each tumor are now well understood because of developments in genomics and molecular biology. This has paved the way for the creation of biological cancer medicines that are specialized to target particular genetic abnormalities or biomarkers found in the cancer cells of the patient. Personalized cancer biological therapies have a number of benefits, including better patient outcomes, lower side effects, and increased therapeutic efficacy. These medicines efficiently restrict tumor growth and proliferation by carefully focusing on the molecular causes of the tumor, improving therapeutic outcomes.

Some locations stand out as potent driving factors in the fascinating world of the market for cancer biological therapies, reshaping the landscape of cancer treatment and research. When it comes to advanced biological medicines and cancer care, North America is by far the dominant region. North America dominates the industry because of its excellent research institutions, sophisticated healthcare infrastructure, and strong emphasis on innovation. The region draws both top biotechnology businesses and healthcare investors because it has a substantial market share and acts as a center for clinical trials and drug development.